These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 33685318

  • 1. Darolutamide in hormone-sensitive and castration-resistant prostate cancer.
    Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R.
    Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318
    [Abstract] [Full Text] [Related]

  • 2. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N.
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [Abstract] [Full Text] [Related]

  • 3. Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors.
    Appukkuttan S, Ko G, Fu C, Bannister B, Kong SX, Jhaveri J, Freedland SJ.
    Expert Rev Anticancer Ther; 2024 May; 24(5):325-333. PubMed ID: 38469875
    [Abstract] [Full Text] [Related]

  • 4. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
    Brave M, Weinstock C, Brewer JR, Chi DC, Suzman DL, Cheng J, Zhang L, Sridhara R, Ibrahim A, Kluetz PG, Pazdur R, Beaver JA.
    Clin Cancer Res; 2020 Sep 15; 26(18):4717-4722. PubMed ID: 32284318
    [Abstract] [Full Text] [Related]

  • 5. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
    Roumiguié M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MO, Lebret T.
    Future Oncol; 2021 May 15; 17(14):1811-1823. PubMed ID: 33543650
    [Abstract] [Full Text] [Related]

  • 6. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K, Mostafaei H, Pradere B, Motlagh RS, Quhal F, Laukhtina E, Schuettfort VM, Abufaraj M, Karakiewicz PI, Kimura T, Egawa S, Shariat SF.
    Int J Clin Oncol; 2020 Nov 15; 25(11):1892-1900. PubMed ID: 32924096
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Recent developments in the treatment of non-metastatic castration resistant prostate cancer.
    Esther J, Dorff TB, Maughan BL.
    Cancer Treat Res Commun; 2020 Nov 15; 24():100181. PubMed ID: 32673844
    [Abstract] [Full Text] [Related]

  • 10. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
    Moussa M, Lazarou L, Dellis A, Abou Chakra M, Papatsoris A.
    Expert Opin Pharmacother; 2021 Mar 15; 22(4):397-402. PubMed ID: 33135506
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    Hussain A, Jiang S, Varghese D, Appukkuttan S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Corman S.
    BMC Cancer; 2022 Mar 22; 22(1):304. PubMed ID: 35317768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI.
    Prostate Cancer Prostatic Dis; 2022 Feb 22; 25(2):139-148. PubMed ID: 34054128
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND.
    Expert Opin Pharmacother; 2017 Jun 22; 18(9):945-952. PubMed ID: 28490267
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 22; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.